

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 12/02/2015

| DENOMINAZIONE FARMACO | PROCEDURA | ATC | PRINCIPIO ATTIVO | TITOLARE | PARERE CHMP | DECISIONE COMMISSIONE | DATA GUUE | data CTS | AIC | Confezione |
|--------------------------------------|----------------------|---------|---------------------------------------|---|-------------|-----------------------|-----------|-----------|-----------|------------|
| BRINTELLIX | EMEA/H/C/2717/PSUV/3 | N06AX26 | Vortioxetine | H. Lundbeck A/S | ott-14 | 16-dic-14 | 30-gen-15 | 16-feb-15 | 043187374 | 37 |
| BRINTELLIX | EMEA/H/C/2717/PSUV/3 | N06AX26 | Vortioxetine | H. Lundbeck A/S | ott-14 | 16-dic-14 | 30-gen-15 | 16-feb-15 | 043187386 | 38 |
| BRINTELLIX | EMEA/H/C/2717/PSUV/3 | N06AX26 | Vortioxetine | H. Lundbeck A/S | ott-14 | 16-dic-14 | 30-gen-15 | 16-feb-15 | 043187398 | 39 |
| BRINTELLIX | EMEA/H/C/2717/PSUV/3 | N06AX26 | Vortioxetine | H. Lundbeck A/S | ott-14 | 16-dic-14 | 30-gen-15 | 16-feb-15 | 043187400 | 40 |
| CYRAMZA | EMEA/H/C/2829 | L01XC | ramucirumab | Eli Lilly Nederland B.V. | nov-14 | 19-dic-14 | 30-gen-15 | 16-feb-15 | 043797012 | 1 |
| CYRAMZA | EMEA/H/C/2829 | L01XC | ramucirumab | Eli Lilly Nederland B.V. | nov-14 | 19-dic-14 | 30-gen-15 | 16-feb-15 | 043797024 | 2 |
| CYRAMZA | EMEA/H/C/2829 | L01XC | ramucirumab | Eli Lilly Nederland B.V. | nov-14 | 19-dic-14 | 30-gen-15 | 16-feb-15 | 043797036 | 3 |
| DUAVIVE | EMEA/H/C/2314 | pending | oestrogens conjugated / bazedoxifene | Pfizer Limited | ott-14 | 16-dic-14 | 30-gen-15 | 16-feb-15 | 043792011 | 1 |
| DULOXETINA LILLY | EMEA/H/C/4000 | N06AX21 | duloxetine | Eli Lilly Nederland B.V. | ott-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043795018 | 1 |
| DULOXETINA LILLY | EMEA/H/C/4000 | N06AX21 | duloxetine | Eli Lilly Nederland B.V. | ott-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043795020 | 2 |
| DULOXETINA LILLY | EMEA/H/C/4000 | N06AX21 | duloxetine | Eli Lilly Nederland B.V. | ott-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043795032 | 3 |
| DULOXETINA LILLY | EMEA/H/C/4000 | N06AX21 | duloxetine | Eli Lilly Nederland B.V. | ott-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043795044 | 4 |
| DULOXETINA LILLY | EMEA/H/C/4000 | N06AX21 | duloxetine | Eli Lilly Nederland B.V. | ott-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043795057 | 5 |
| DULOXETINA LILLY | EMEA/H/C/4000 | N06AX21 | duloxetine | Eli Lilly Nederland B.V. | ott-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043795069 | 6 |
| DULOXETINA LILLY | EMEA/H/C/4000 | N06AX21 | duloxetine | Eli Lilly Nederland B.V. | ott-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043795071 | 7 |
| DULOXETINA LILLY | EMEA/H/C/4000 | N06AX21 | duloxetine | Eli Lilly Nederland B.V. | ott-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043795083 | 8 |
| DULOXETINA LILLY | EMEA/H/C/4000 | N06AX21 | duloxetine | Eli Lilly Nederland B.V. | ott-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043795095 | 9 |
| EXVIERA | EMEA/H/C/3837 | Pending | dasabuvir | AbbVie Ltd | nov-14 | 15-gen-14 | PENDING | 16-feb-15 | 043840014 | 1 |
| LYNPARZA | EMEA/H/C/3726 | Pending | Olaparib | AstraZeneca AB | nov-14 | 16-dic-14 | 30-gen-15 | 16-feb-15 | 043794015 | 1 |
| MOVENTIG | EMEA/H/C/2810 | A06AH03 | naloxegol | AstraZeneca AB | set-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043793013 | 1 |
| MOVENTIG | EMEA/H/C/2810 | A06AH03 | naloxegol | AstraZeneca AB | set-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043793025 | 2 |
| MOVENTIG | EMEA/H/C/2810 | A06AH03 | naloxegol | AstraZeneca AB | set-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043793037 | 3 |
| MOVENTIG | EMEA/H/C/2810 | A06AH03 | naloxegol | AstraZeneca AB | set-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043793049 | 4 |
| MOVENTIG | EMEA/H/C/2810 | A06AH03 | naloxegol | AstraZeneca AB | set-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043793052 | 5 |
| MOVENTIG | EMEA/H/C/2810 | A06AH03 | naloxegol | AstraZeneca AB | set-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043793064 | 6 |
| MOVENTIG | EMEA/H/C/2810 | A06AH03 | naloxegol | AstraZeneca AB | set-14 | 08-dic-14 | 30-gen-15 | 16-feb-15 | 043793076 | 7 |
| OFEV | EMEA/H/C/3821 | L01XE31 | Nintedanib | Boehringer Ingelheim International GmbH | nov-14 | 15-gen-15 | PENDING | 16-feb-15 | 043827017 | 1 |
| OFEV | EMEA/H/C/3821 | L01XE31 | Nintedanib | Boehringer Ingelheim International GmbH | nov-14 | 15-gen-15 | PENDING | 16-feb-15 | 043827029 | 2 |
| OFEV | EMEA/H/C/3821 | L01XE31 | Nintedanib | Boehringer Ingelheim International GmbH | nov-14 | 15-gen-15 | PENDING | 16-feb-15 | 043827031 | 3 |
| OFEV | EMEA/H/C/3821 | L01XE31 | Nintedanib | Boehringer Ingelheim International GmbH | nov-14 | 15-gen-15 | PENDING | 16-feb-15 | 043827043 | 4 |
| PALIPERIDONE JANSSEN | non presente | N05AX13 | paliperidone | Janssen-Cilag International NV | ott-14 | 05-dic-14 | 30-gen-15 | 16-feb-15 | 043799016 | 1 |
| PALIPERIDONE JANSSEN | non presente | N05AX13 | paliperidone | Janssen-Cilag International NV | ott-14 | 05-dic-14 | 30-gen-15 | 16-feb-15 | 043799026 | 2 |
| PALIPERIDONE JANSSEN | non presente | N05AX13 | paliperidone | Janssen-Cilag International NV | ott-14 | 05-dic-14 | 30-gen-15 | 16-feb-15 | 043799038 | 3 |
| PALIPERIDONE JANSSEN | non presente | N05AX13 | paliperidone | Janssen-Cilag International NV | ott-14 | 05-dic-14 | 30-gen-15 | 16-feb-15 | 043799040 | 4 |
| PALIPERIDONE JANSSEN | non presente | N05AX13 | paliperidone | Janssen-Cilag International NV | ott-14 | 05-dic-14 | 30-gen-15 | 16-feb-15 | 043799053 | 5 |
| PALIPERIDONE JANSSEN | non presente | N05AX13 | paliperidone | Janssen-Cilag International NV | ott-14 | 05-dic-14 | 30-gen-15 | 16-feb-15 | 043799065 | 6 |
| RIXUBIS | EMEA/H/C/3771 | B02BD04 | nonacog gamma | Baxter Innovations GmbH | ott-14 | 19-dic-14 | 30-gen-15 | 16-feb-15 | 043796010 | 1 |
| RIXUBIS | EMEA/H/C/3771 | B02BD04 | nonacog gamma | Baxter Innovations GmbH | ott-14 | 19-dic-14 | 30-gen-15 | 16-feb-15 | 043796022 | 2 |
| RIXUBIS | EMEA/H/C/3771 | B02BD04 | nonacog gamma | Baxter Innovations GmbH | ott-14 | 19-dic-14 | 30-gen-15 | 16-feb-15 | 043796034 | 3 |
| RIXUBIS | EMEA/H/C/3771 | B02BD04 | nonacog gamma | Baxter Innovations GmbH | ott-14 | 19-dic-14 | 30-gen-15 | 16-feb-15 | 043796046 | 4 |
| RIXUBIS | EMEA/H/C/3771 | B02BD04 | nonacog gamma | Baxter Innovations GmbH | ott-14 | 19-dic-14 | 30-gen-15 | 16-feb-15 | 043796059 | 5 |
| SCENESSE | EMEA/H/C/2548 | D02BB02 | afamelanotide | Clinuvel UK Limited | nov-14 | 22-dic-14 | 30-gen-15 | 16-feb-15 | 043798014 | 1 |
| VIEKIRAX | EMEA/H/C/3839 | Pending | ombitasvir / paritaprevir / ritonavir | AbbVie Ltd | nov-14 | 15-gen-14 | PENDING | 16-feb-15 | 043841016 | 1 |

La responsabilità di qualsiasi onere e/o attività che l' Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all' immissione in commercio del medicinale, è totalmente a carico dell' Azienda stessa. L' ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.